SELLAS Life Sciences Group, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.6M | $-8.4M | $-6.8M | $-6.6M | $-5.8M | $-7.1M | $-7.5M | $-9.6M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $798.0K | — | — | $505.0K | — | — | $476.0K |
| Net Cash from Operating Activities | $-7.6M | $-8.8M | $-7.1M | $-7.3M | $-9.1M | $-7.8M | $-9.7M | $-10.8M |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $44.2M | — | — | $23.6M | — | — | $26.6M |
| Net Change in Cash | — | $35.3M | — | — | $14.5M | — | — | $15.9M |
| Free Cash Flow | — | — | — | — | — | — | — | — |